Demonstration of in vivo stability and lack of immunogenicity of a polyethyleneglycol-conjugated recombinant CHO-derived butyrylcholinesterase bioscavenger using a homologous macaque model

Chemico-Biological Interactions

Volumn 187, Issue 1-3, 2010, Pages 279-286

  Rosenberg, Yvonne J ^a   Saxena, Ashima ^b   Sun, Wei ^b   Jiang, Xiaoming ^a   Chilukuri, Nageswararao ^b   Luo, Chunjuan ^b   Doctor, Bhupendra P ^b   Lee, Keunmyoung D ^a  

^a PlantVax Corporation   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Butyrylcholinesterase; Homologous model; Immunogenicity; Macaque; Pharmacokinetics

Indexed keywords

CHOLINESTERASE; DRUG ANTIBODY; MACROGOL; RECOMBINANT CHOLINESTERASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG ANTIGENICITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG STABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOGENICITY; MACACA; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; SINGLE DRUG DOSE;

ANIMALIA; MACACA; RODENTIA;

EID: 77955511979     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.02.042     Document Type: Article

References (31)

1. Doctor B.P., Maxwell D.M., Ashani Y., Saxena A., Gordon R.K. New approaches to medical protection against chemical warfare nerve agents. Chemical Warfare Nerve Agents, Toxicity at Low Levels 2001, 191-214. CRC Press, Washington, DC. J.A. Romano (Ed.).
2. Lenz D.E., Broomfield C.A., Maxwell D.M., Cerasoli D.M. Nerve agent bioscavengers: protection against high- and low-dose organophosphorus exposure. Chemical Warfare Agents, Toxicity as Low Levels 2001, 215-243. CRC Press, Washington, DC. J.A. Romano (Ed.).
3. Lenz D.E., Yeung D., Smith J.R., Sweeney R.E., Lumley L.A., Cerasoli D.M. Stoichiometric and catalytic scavengers as protection against nerve agent toxicity: a mini review. Toxicology 2007, 233:31-39. (review).
4. Lockridge O., Bartels C.F., Vaughan T.A., Wong C.K., Norton S.E., Johnson L.L. Complete amino acid sequence of human serum cholinesterase. Biol. Chem. 1987, 262:549-557.
5. Raveh L., Grauer E., Grunwald J., Cohen E., Ashani Y. The stoichiometry of protection against soman and VX toxicity in monkeys pretreated with human butyrylcholinesterase. Toxicol. Appl. Pharmacol. 1997, 145:43-53.
6. Ashani Y., Pistinner S. Estimation of the upper limit of human butyrylcholinesterase dose required for protection against organophosphates toxicity: a mathematically based toxicokinetic model. Toxicol. Sci. 2004, 77:358-367.
7. Duysen E.G., Bartels C.F., Lockridge O. Wild-type and A328W mutant human butyrylcholinesterase tetramers expressed in Chinese hamster ovary cells have a 16-hour half-life in the circulation and protect mice from cocaine toxicity. J. Pharmacol. Exp. Ther. 2002, 303:751-758.
8. Huang Y.J., Huang Y., Baldassarre H., Wang B., Lazaris A., Leduc M., Bilodeau A.S., Bellemare A., Côté M., Herskovits P., Touati M., Turcotte C., Valeanu L., Lemée N., Wilgus H., Bégin I., Bhatia B., Rao K., Neveu N., Brochu E., Pierson J., Hockley D.K., Cerasoli D.M., Lenz D.E., Karatzas C.N., Langermann S. Recombinant human butyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoning. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:13603-13608.
9. Geyer B.C., Woods R.R., Mor T.S. Increased organophosphate scavenging in a butyrylcholinesterase mutant. Chem. Biol. Interact. 2008, 175:376-379.
10. Saxena A., Ashani Y., Raveh L., Stevenson D., Patel T., Doctor B.P. Role of oligosaccharides in the pharmacokinetics of tissue-derived and genetically engineered cholinesterases. Mol. Pharmacol. 1998, 53:112-122.
11. Kolarich D., Weber A., Pabst M., Stadlmann J., Teschner W., Ehrlich H., Schwarz H.P., Altmann F. Glycoproteomic characterization of butyrylcholinesterase from human plasma. Proteomics 2008, 8:254-263.
12. Varki A. N-Glycolylneuraminic acid deficiency in humans. Biochimie 2001, 83:615-622. (review).
13. Park E.I., Mi Y., Unverzagt C., Gabius H.J., Baenziger J.U. The asialoglycoprotein receptor clears glycoconjugates terminating with sialic acid alpha 2, 6GalNAc. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:17125-17129.
14. Chung C.H., Mirakhur B., Chan E., Le Q.T., Berlin J., Morse M., Murphy B.A., Satinover S.M., Hosen J., Mauro D., Slebos R.J., Zhou Q., Gold D., Hatley T., Hicklin D.J., Platts-Mills T.A. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N. Engl. J. Med. 2008, 358:1109-1117.
15. Diaz S.L., Padler-Karavani V., Ghaderi D., Hurtado-Ziola N., Yu H., Chen X., Brinkman-Van der Linden E.C., Varki A., Varki N.M. Sensitive and specific detection of the non-human sialic acid N-glycolylneuraminic acid in human tissues and biotherapeutic products. PLoS One 2009, 4:e4241.
16. Altmann F. The role of protein glycosylation in allergy. Int. Arch. Allergy Immunol. 2007, 142:99-115. (review).
17. Genovese R.F., Lu X.C., Gentry M.K., Larrison R., Doctor B.P. Evaluation of purified horse serum butrylcholinesterase in rats. Proc. Med. Defense Biosci. Rev. 1993, 3:1035-1042.
18. Matzke S.M., Oubre J.L., Caranto G.R., Gentry M.K., Galbicka G. Behavioral and immunological effects of exogenous butyrylcholinesterase in rhesus monkeys. Pharmacol. Biochem. Behav. 1999, 62:523-530.
19. Gentry M.K., Nuwayer E.S., Doctor B.P. Proc. Med. Defense Biosci. Rev. 1996, 1:183-191.
20. Rosenberg Y., Luo C., Ashani Y., Doctor B.P., Fischer R., Wolfe G., Saxena A. Pharmacokinetics and immunologic consequences of exposing macaques to purified homologous butyrylcholinesterase. Life Sci. 2002, 72:125-134.
21. Jenkins T., Balinsky D., Patient D.W. Cholinesterase in plasma, first reported absence in the Bantu; half-life determination. Science 1967, 156:1748-1750.
22. Cascio C., Comite C., Ghiara M., Lanza G., Ponchione A. Use of serum cholinesterases in severe organophosphorus poisoning. Our experience. Minerva Anestesiol. 1988, 54:337-338.
23. Chilukuri N., Sun W., Parikh K., Naik R.S., Tang L., Doctor B.P., Saxena A. A repeated injection of polyethyleneglycol-conjugated recombinant human butyrylcholinesterase elicits immune response in mice. Toxicol. Appl. Pharmacol. 2008, 231:423-429.
24. Altamirano C.V., Lockridge O. Association of tetramers of human butyrylcholinesterase is mediated by conserved aromatic residues of the carboxy terminus. Chem. Biol. Interact. 1999, 14:53-60.
25. Saxena A., Luo C., Doctor B.P. Developing procedures for the large-scale purification of human serum butyrylcholinesterase. Protein Expr. Purif. 2008, 61:191-196.
26. Ellman G.L., Courtney K.D., Andres V., Feather-stone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7:88-95.
27. Kronman C., Cohen O., Raveh L., Mazor O., Ordentlich A., Shafferman A. Polyethylene-glycol conjugated recombinant human acetylcholinesterase serves as an efficacious bioscavenger against soman intoxication. Toxicology 2007, 233:40-46.
28. Laub P.B., Gallo J.M. NCOMP-a windows-based computer program for noncompartmental analysis of pharmacokinetic data. J. Pharm. Sci. 1996, 85:393-395.
29. Kronman C., Chitlaru T., Elhanany E., Velan B., Shafferman A. Hierarchy of post-translational modifications involved in the circulatory longevity of glycoproteins. Demonstration of concerted contributions of glycan sialylation and subunit assembly to the pharmacokinetic behavior of bovine acetylcholinesterase. J. Biol. Chem. 2000, 275:29488-29502.
30. Kang J.S., Deluca P.P., Lee K.C. Emerging PEGylated drugs. Expert Opin. Emerg. Drugs 2009, 14:363-380. (review).
31. Pepinsky R.B., LePage D.J., Gill A., Chakraborty A., Vaidyanathan S., Green M., Baker D.P., Whalley E., Hochman P.S., Martin P. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity. J. Pharmacol. Exp. Ther. 2001, 297:1059-1066.